Venture Valuation specializes in independent asset and company valuation of biotechnology, biopharma, life sciences and medical technology. Valuations are provided for fundraising, investment decision, portfolio valuations, in- and out-licensing, arbitration/fairness opinions and M&A. The company has developed “Biotechgate”, which is business development and licensing database for the life sciences industry. Company Valuation: The Company Valuation Reports include a thorough assessment of the company by experienced professionals with expertise in the relevant fields as well as the following elements: • summary of key risk parameters and strengths of the company • outline of the crucial factors and value drivers for growth and further strategic development • assessment of the management, market, science, technology and products • analysis of the company’s business model and the company’s competitive environment • detailed calculation of the company’s financial value, using appropriate valuation methods Product Valuation: Venture Valuation offers detailed Product Valuation Reports of pre-clinical and clinical products in development that can serve as a basis for negotiations or to structure different deal scenarios. The Product Valuation includes: • detailed analysis of development costs, time lines, patient population, competing products, pricing and product life cycle • industry gold standard rNPV valuation methodology based on indication-specific attrition rates and the development stage • scenario and sensitivity analyses • analysis of the current value, and forecasts of the future value following the successful completion of key development milestones As an “add on” module and based on Venture Valuation’s deal database within Biotechgate, benchmarking deals can also be included to provide the client with a differentiated negotiation basis and comparable information.
UNLV Office of Technology Transfer and Economic Development
UNLV is Nevada’s premier public research university and a powerhouse for groundbreaking discovery and innovation, particularly in life sciences and biotechnology. At the forefront of UNLV’s industry and business engagement are our dynamic offices of Economic Development and Technology Transfer, serving as vital connectors between pioneering research and impactful commercialization opportunities. UNLV’s cutting-edge Brain Health Department as well as the innovative Wastewater Surveillance Laboratory exemplify our bold approach to solving complex health and environmental challenges. Researchers at these centers drive groundbreaking advancements with profound implications for neuroscience, public health, environmental monitoring, and disease prevention. Uniquely situated within a collaborative and vibrant regional ecosystem, UNLV thrives alongside major stakeholders committed to ambitious, strategic coordination and innovative thinking. This environment enables business and industry partnerships to flourish, supported by open communication and outside-the-box planning that accelerate shared success. At BIO International 2025, our goal is clear: to connect industry leaders, visionaries, and partners directly with UNLV’s exceptional talent, transformative research capabilities, and rich pipeline of licensable technologies. Opportunities abound at UNLV for collaborative sponsored research, tailored workforce development programs, robust startup incubation support, and access to patented university technologies poised for commercialization. Discover how partnering with UNLV can propel your organization’s priorities forward through innovative solutions and collaborations. Connect with us at BIO to harness the full potential of our research excellence and vibrant innovation ecosystem. | UNLV, a Carnegie R1 research institution, is a key player in the delegation’s efforts. UNLV emphasizes industry engagement through opportunities for students, strong bio research, innovation, a collaborative research and technology park, and commercialization of life-changing products in fields like life science, physical science, and engineering. UNLV is seeking to connect with BIOtech companies and explore collaboration opportunities.
Pathway to Cures/NBDF
Pathway to Cures (P2C) is the National Bleeding Disorders Foundation’s (NBDF) venture philanthropy fund created specifically to accelerate the development of cures and therapies across all inheritable blood and bleeding disorders. P2C makes investments in innovative therapies, and technologies, leveraging the deep resources and scientific community relationships of NBDF. NBDF provides services that allow developers to engage with and obtain insights from community members with an inheritable bleeding disorder.
Osborne Clarke
Osborne Clarke is an international legal practice with over 2,800 employees at 26 locations worldwide. With the claim “Helping you succeed in tomorrow’s world”, extensive industry knowledge in the Life Sciences and Healthcare industry and outstanding expertise in the digital transformation of business models, Osborne Clarke advises and represents companies, entrepreneurs and investors in all practical business law issues focusing not only on our chosen sectors but also on the three key topics of digital transformation, decarbonisation and urban dynamics.
Novalis VC
Novalis Biotech is an early stage venture capital investor in life sciences. We welcome innovative concepts in TechBio and aim to support their development already at the state of incorporation. Our investment focus is “enabling technologies” in life sciences. We strongly believe in capital light platform technology and close interaction with customers already early in the life of the company. Focus areas are: innovative research and manufacturing tools, bioinformatics, genomics, diagnostics and digital health. We focus on early-stage start-ups, from (pre-)seed stage to series A, and support their evolution by providing funding, sharing our professional and academic connections, and helping to shape the business strategy in order to create value for all stakeholders.
New York Ventures
New York Ventures, a division of Empire State Development, is an early-stage venture capital fund that invests in high growth start-up companies across all regions of New York State. We administer the state’s innovation investment funds by partnering with entrepreneurs to build the future of New York, prioritizing companies that solve important challenges in the areas of life sciences, climate tech, agriculture, information sciences and other emerging technologies. New York Ventures is actively deploying over $300 million of capital through equity programs for both direct and indirect investment.
Linearis
Linearis is transforming healthcare by merging artificial intelligence and biomarker analysis to enhance patient care with more precise, accessible prevention, detection, treatment of metabolic diseases including cancer, diabetes, and antimicrobial resistance. The team unites unparalleled, world-renowned experts in biomarker discovery, drug development, biopharma, and healthcare innovation. Alexandre Le Bouthillier, a serial AI entrepreneur and CEO, collaborates with Jacques Corbeil, holder of the Canada Research Chair in Medical Genomics and CSO, and Manon Boisclair, a global biopharma executive and COO/CCO. Together, they have discovered and internationally marketed medical diagnostics and treatments. Contributions from Yoshua Bengio, a co-father of modern AI and Turing Prize winner, David Wishart, curator of the Human Metabolome Database, bolster Linearis’ efforts in providing the first certified industrial laboratory that combines high-throughput metabolomic analysis and AI. | Linearis with its tandem Ventures Fund and Laboratory is pioneering and supporting discoveries to prevent, detect, and cure metabolomic diseases including cancer & diabetes through direct investments in innovative AI-powered life sciences companies. Linearis Ventures leverage its AI and multi-omics expertise to support life science companies’ growth, accelerating their trailblazing innovation and advancing biomarkers to provide critical insights into a broad spectrum of health conditions. Linearis Labs provide services to large biobanks, CROs and BioPharma companies across their life cycle management from drug discovery, patient screening, disease prevention as well as treatment monitoring.
Life Sciences Greenhouse Investments
A public/private evergreen venture fund that invests in early-stage life science companies with substantive ties to Pennsylvania, USA. • Average Ticket: initial investment of $250,000 – $500,000 ; follow-on funding of $1-2M • Investment Stage: seed through Series A for initial investment • Sector: human health, including novel therapeutics; medical devices; diagnostics; clinical-facing IT; and tools that facilitate discovery, R&D, and scale-up. Will consider ag-tech and animal health technologies with the potential to impact human health